Phase 3 data support use of the oral non-peptide small molecule as potential first-line type 2 diabetes treatment, investigator says.

A new weight loss treatment that can be taken as either a daily pill or a weekly injection has shown very promising results ...

The new Ozempic? Weight-loss pill Amycretin could be more effective than jabs - Those who took the pill lost around 13 per cent of their body weight over three months ...

Novo Nordisk rebounds from 2024 lows as GLP-1 supply issues ease, partnerships expand, and valuation turns attractive. Find ...

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...

A new generation of weight-loss drugs has proven remarkably effective, hugely popular and massively lucrative in the last few ...

Novo Nordisk shows strong fundamentals and long-term return potential despite valuation concerns and US pricing risks. Find ...

Novo Nordisk on Friday said full results from early-stage trials show that its experimental drug, amycretin, helped ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Among patients with moderate peripheral artery disease, GLP-1 use was associated with reduced risk for cardiovascular and ...